Issue of equity from exercise of share options

24 April 2015

Midatech Pharma PLC

("Midatech" or the "Company")

Issue of equity from exercise of share options

Midatech (AIM: MTPH), the international specialty pharmaceutical with a diversified portfolio of high-value assets, today announces the issue and allotment of 16,500 new ordinary shares of 0.005 pence each in the Company (the "New Ordinary Shares") pursuant to the exercise of share options by a former employee.

Application has been made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on 30 April 2015. The New Ordinary Shares will rank pari passu with the existing shares of the Company.

Following the exercise of options, the Company will have 27,810,760 ordinary shares in issue, none of which is in treasury. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company.

For more information, please contact:

Midatech Pharma PLC

Jim Phillips, CEO

Tel: +44 (0)1235 841575

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Corporate Finance

Freddy Crossley / Adam James / Atholl Tweedie / Duncan Monteith

Broking

Tom Salvesen

Tel: +44 (0)20 7886 2500

Consilium Strategic Communications (Financial PR)

Mary Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik Thys

Tel: +44 (0)20 3709 5700

Email: [email protected]

About Midatech Pharma PLC

Midatech Pharma is a nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs. The Group has a strong pipeline of product candidates in clinical and pre-clinical development with a clear focus on the key therapeutic areas of diabetes, cancer and neurological/ophthalmological diseases.

Right place. Right time. Central to Midatech's business are two platform technologies that are designed to enable the targeted delivery and controlled release of existing drugs. Midatech's core platform is a pioneering drug conjugate delivery system based on gold-nanoparticles (GNPs) combined with existing drugs for targeted release at specific organs, cells or sites of disease. The Group's secondary platform (acquired through the acquisition of Q Chip in 2014) involves the consistent and precise encapsulation of active drug compounds within polymer microspheres that are designed to release the drug into the body in a highly controlled manner over a prolonged period of time.

The Group has collaborations with a number of speciality and major pharmaceutical companies and academic institutions to develop its platform technologies across a broad range of programmes within Midatech's priority therapeutic areas. The business strategy is to expedite the pipeline developments into revenue opportunities.

Midatech operates an in-house state-of-the-art nanoparticle manufacturing facility, based in Bilbao, Spain. The site has capacity for manufacturing sufficient materials for clinical trials and is fully licensed by the Spanish Medicines Agency for European compliance.

The Group is headquartered in Oxford, UK and employs 53 staff including 14 in Oxford, UK, 17 in Cardiff, UK and 18 in Bilbao, Spain. Across the Group there are 32 qualified scientists. For further company information see: www.midatechgroup.com.